Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Department of Veterans Affairs |
---|---|
Information provided by: | Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00108563 |
The purpose of this study is to learn more about the effects of interferon and ribavirin combination therapy in people with Hepatitis C. The specific aims are:
Condition | Intervention | Phase |
---|---|---|
Hepatitis C Depression |
Drug: Citalopram or Placebo |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study |
Official Title: | VISN 20 Prophylactic Treatment of IFN-Induced Depression in Hepatitis C |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CLIN-012-02S |
Study First Received: | April 15, 2005 |
Last Updated: | March 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00108563 |
Health Authority: | United States: Federal Government |
Hepatitis C Depression Interferon-alpha |
Citalopram ribavirin antidepressive agents |
Interferon-alpha Liver Diseases Depression Interferons Ribavirin Hepatitis, Viral, Human Depressive Disorder Citalopram Serotonin |
Behavioral Symptoms Hepatitis Virus Diseases Digestive System Diseases Mental Disorders Mood Disorders Hepatitis C Dexetimide Interferon Alfa-2a |
RNA Virus Infections Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Flaviviridae Infections Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs |
Serotonin Uptake Inhibitors Pharmacologic Actions Serotonin Agents Therapeutic Uses Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |